VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
LGVNLongeveron Inc.
$0.82$18M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

LGVN logoLongeveron Inc.(LGVN)Earnings, Financials & Key Ratios

LGVN•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCell and Gene Therapy Developers
AboutLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.Show more
  • Revenue$1M-49.9%
  • EBITDA-$22M-41.7%
  • Net Income-$23M-42.1%
  • EPS (Diluted)-1.29-20.6%
  • Gross Margin66.97%-15.0%
  • EBITDA Margin-1839.87%-182.8%
  • Operating Margin-1942.2%-181.2%
  • Net Margin-1893.58%-183.6%
  • ROE-164.75%-47.6%

LGVN Key Insights

Longeveron Inc. (LGVN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Profits declining 43.6% over 5 years
  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Sales declining 26.6% over 5 years
  • ✗Shares diluted 18.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when LGVN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LGVN Price & Volume

Longeveron Inc. (LGVN) stock price & volume — 10-year historical chart

Loading chart...

LGVN Growth Metrics

Longeveron Inc. (LGVN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-26.6%
3 Years-0.63%
TTM-45.35%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-32.53%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM58.63%

Return on Capital

10 Years-88.95%
5 Years-107.42%
3 Years-134.22%
Last Year-159.77%

LGVN Recent Earnings

Longeveron Inc. (LGVN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.19+0.0%
$0.19
Rev
$398,000+19.0%
$334,500
Q2 2026
Mar 17, 2026
Metric
Actual
Est
EPS
$0.22+47.6%
$0.42
Rev
$365,000+230.8%
$110,333
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$0.39-50.0%
$0.26
Rev
$137,000+24.2%
$110,330
Q3 2025
Aug 13, 2025
Metric
Actual
Est
EPS
$0.33+5.7%
$0.35
Rev
$316,000-28.8%
$444,000
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.19vs $0.19+0.0%
$398,000vs $334,500+19.0%
Q2 2026Mar 17, 2026
$0.22vs $0.42+47.6%
$365,000vs $110,333+230.8%
Q4 2025Nov 4, 2025
$0.39vs $0.26-50.0%
$137,000vs $110,330+24.2%
Q3 2025Aug 13, 2025
$0.33vs $0.35+5.7%
$316,000vs $444,000-28.8%
Based on last 12 quarters of dataView full earnings history →

LGVN Peer Comparison

Longeveron Inc. (LGVN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
MESO logoMESOMesoblast LimitedDirect Competitor1.85B14.37-17.11191.39%-5.94%-17.1%0.21
NKTR logoNKTRNektar TherapeuticsDirect Competitor1.19B60.98-6.27-43.89%-284.18%-87%1.66
BCLI logoBCLIBrainstorm Cell Therapeutics Inc.Direct Competitor9.54M0.86-0.78
PLUR logoPLURPluri Inc.Direct Competitor18.16M2.02-0.57309.82%-24.25%-9.93%
FATE logoFATEFate Therapeutics, Inc.Product Competitor243.61M2.09-1.82-51.24%-20.57%-58.89%0.38
CELH logoCELHCelsius Holdings, Inc.Product Competitor7.87B30.80123.2085.54%5.85%7.51%0.23
RCEL logoRCELAVITA Medical, Inc.Product Competitor99.62M4.01-2.3011.45%-62.67%
MDXG logoMDXGMiMedx Group, Inc.Product Competitor545.24M3.6711.4719.99%7.88%12.86%0.09

Compare LGVN vs Peers

Longeveron Inc. (LGVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MESO

Most directly comparable listed peer for LGVN.

Scale Benchmark

vs IQV

Larger-name benchmark to compare LGVN against a more recognizable public peer.

Peer Set

Compare Top 5

vs MESO, NKTR, BCLI, PLUR

LGVN Income Statement

Longeveron Inc. (LGVN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
2.13M5.63M5.63M1.31M1.22M709K2.39M1.2M1.22M
Revenue Growth %
-163.71%-0.01%-76.8%-6.43%-41.98%237.38%-49.87%-45.35%
Cost of Goods Sold
1.45M3.8M3.8M716K725K488K508K396K424K
COGS % of Revenue
68.12%67.56%67.56%54.82%59.33%68.83%21.24%33.03%-
Gross Profit
680.65K▲ 0%
1.83M▲ 168.3%
1.83M▼ 0.0%
590K▼ 67.7%
497K▼ 15.8%
221K▼ 55.5%
1.88M▲ 752.5%
803K▼ 57.4%
792K▲ 0%
Gross Margin %
31.88%32.44%32.44%45.18%40.67%31.17%78.76%66.97%65.13%
Gross Profit Growth %
-168.31%-0.01%-67.69%-15.76%-55.53%752.49%-57.38%-
Operating Expenses
7.04M5.6M5.6M18.05M18.54M21.25M18.41M24.09M23.67M
OpEx % of Revenue
329.84%99.56%99.56%1381.78%1517.18%2997.18%769.48%2009.17%-
Selling, General & Admin
3.17M2.93M2.93M10.95M9.17M12.18M10.27M12.05M11.83M
SG&A % of Revenue
148.28%52.05%52.05%838.74%750.41%1718.48%429.31%1004.92%-
Research & Development
3.88M2.67M2.67M7.09M9.37M9.07M8.14M12.04M11.85M
R&D % of Revenue
181.56%47.51%47.5%543.03%766.78%1278.7%340.18%1004.25%-
Other Operating Expenses
000000000
Operating Income
-6.36M▲ 0%
-3.78M▲ 40.6%
-3.78M▲ 0.0%
-17.46M▼ 362.0%
-18.04M▼ 3.4%
-21.03M▼ 16.5%
-16.52M▲ 21.4%
-23.29M▼ 40.9%
-22.88M▲ 0%
Operating Margin %
-297.95%-67.12%-67.12%-1336.6%-1476.51%-2966.01%-690.72%-1942.2%-1881.66%
Operating Income Growth %
-40.6%0.01%-362.04%-3.36%-16.55%21.43%-40.95%-
EBITDA
-5.61M-3.01M-2.99M-16.54M-17.15M-20.08M-15.56M-22.06M-22.08M
EBITDA Margin %
-263.02%-53.46%-53.17%-1266.62%-1403.44%-2832.58%-650.67%-1839.87%-1815.46%
EBITDA Growth %
-46.4%0.55%-452.69%-3.68%-17.1%22.5%-41.74%-33.92%
D&A (Non-Cash Add-back)
745.77K768.84K785K914K893K946K958K1.23M805K
EBIT
-6.34M-3.71M-3.71M-17.04M-18.04M-21.03M-16.52M-23.29M-22.42M
Net Interest Income
23.82K2.77K-6.4K-4K00000
Interest Income
23.82K2.94K139000000
Interest Expense
01696.54K4K00000
Other Income/Expense
23.82K57.47K57K411K-792K-384K549K583K452K
Pretax Income
-6.34M▲ 0%
-3.72M▲ 41.3%
-3.72M▼ 0.0%
-17.05M▼ 358.1%
-18.84M▼ 10.5%
-21.41M▼ 13.7%
-15.97M▲ 25.4%
-22.7M▼ 42.1%
-22.43M▲ 0%
Pretax Margin %
-296.84%-66.09%-66.1%-1305.13%-1541.33%-3020.17%-667.77%-1893.58%-1844.49%
Income Tax
23.82K00000000
Effective Tax Rate %
-0.38%0%0%0%0%0%0%0%0%
Net Income
-6.34M▲ 0%
-3.72M▲ 41.3%
-3.72M▼ 0.0%
-17.05M▼ 358.1%
-18.84M▼ 10.5%
-21.41M▼ 13.7%
-15.97M▲ 25.4%
-22.7M▼ 42.1%
-22.43M▲ 0%
Net Margin %
-296.84%-66.09%-66.1%-1305.13%-1541.33%-3020.17%-667.77%-1893.58%-1844.49%
Net Income Growth %
-41.28%-0.01%-358.08%-10.5%-13.69%25.41%-42.14%-32.53%
Net Income (Continuing)
-6.34M-3.72M-3.72M-17.05M-18.84M-21.41M-15.97M-22.7M-22.43M
Discontinued Operations
000000000
Minority Interest
000000000
EPS (Diluted)
-3.98▲ 0%
-1.87▲ 53.0%
-2.21▼ 18.2%
-9.00▼ 307.2%
-9.00▲ 0.0%
-10.22▼ 13.6%
-1.07▲ 89.5%
-1.29▼ 20.6%
-0.90▲ 0%
EPS Growth %
-53.02%-18.18%-307.24%0%-13.56%89.53%-20.56%58.63%
EPS (Basic)
-3.98-1.87-2.21-9.00-9.00-10.22-1.07-1.29-
Diluted Shares Outstanding
1.59M1.6M1.69M1.89M2.1M2.17M14.89M17.58M24.79M
Basic Shares Outstanding
1.59M1.6M1.69M1.89M2.1M2.17M14.89M17.58M24.79M
Dividend Payout Ratio
---------

LGVN Balance Sheet

Longeveron Inc. (LGVN) balance sheet — assets, liabilities & shareholders' equity

MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
4.16M2.37M1.85M35.38M20.28M5.85M19.62M5.45M16.86M
Cash & Short-Term Investments
4.03M1.87M816K35.04M19.66M5.36M19.23M4.66M15.76M
Cash Only
4.03M1.87M816K25.66M10.5M4.95M19.23M4.66M15.76M
Short-Term Investments
0009.38M9.15M412K000
Accounts Receivable
0451.46K420K55K218K111K84K104K68K
Days Sales Outstanding
-29.2727.2315.3765.1157.1412.8231.6619.14
Inventory
000000000
Days Inventory Outstanding
---------
Other Current Assets
00561K0404K376K308K686K1.03M
Total Non-Current Assets
6.36M8.21M7.39M7.39M7.13M6.23M5.93M4.81M4.36M
Property, Plant & Equipment
4.76M6.48M5.67M4.88M4.48M3.75M3.33M2.35M2.1M
Fixed Asset Turnover
0.45x0.87x0.99x0.27x0.27x0.19x0.72x0.51x0.48x
Goodwill
000000000
Intangible Assets
1.35M1.48M1.55M2.33M2.41M2.29M2.4M2.29M2.24M
Long-Term Investments
0000000100K100K
Other Non-Current Assets
250.89K250.89K177K177K244K193K202K76K18K
Total Assets
10.52M▲ 0%
10.58M▲ 0.6%
9.24M▼ 12.7%
42.77M▲ 362.8%
27.41M▼ 35.9%
12.08M▼ 55.9%
25.56M▲ 111.6%
10.26M▼ 59.9%
21.21M▲ 0%
Asset Turnover
0.20x0.53x0.61x0.03x0.04x0.06x0.09x0.12x0.08x
Asset Growth %
-0.6%-12.7%362.84%-35.9%-55.94%111.61%-59.85%-119.74%
Total Current Liabilities
1.86M2.49M3.83M2.71M4.87M3.89M2.58M4.09M4.34M
Accounts Payable
1.21M1.15M1.59M645K1.75M638K99K423K293K
Days Payables Outstanding
302.57110.82152.6328.81881.54477.1971.13389.89537.17
Short-Term Debt
00177K0000655K688K
Deferred Revenue (Current)
405K541.79K10K199K506K506K40K40K182K
Other Current Liabilities
209.26K0001.4M002.97M3.26M
Current Ratio
2.24x0.95x0.48x13.06x4.17x1.50x7.60x1.33x3.88x
Quick Ratio
2.24x0.95x0.48x13.06x4.17x1.50x7.60x1.33x3.88x
Cash Conversion Cycle
---------518.03
Total Non-Current Liabilities
1.84M3.65M3.45M2.6M2.04M1.45M1.09M499K838K
Long-Term Debt
00311K000000
Capital Lease Obligations
03.65M3.14M2.6M2.04M1.45M824K169K1.07M
Deferred Tax Liabilities
000000000
Other Non-Current Liabilities
1.84M00000265K330K778K
Total Liabilities
3.71M6.14M7.28M5.31M6.91M5.34M3.67M4.59M5.18M
Total Debt
04.14M4.14M3.14M2.6M2.04M1.45M824K748K
Net Debt
-4.03M2.27M3.33M-22.52M-7.9M-2.91M-17.79M-3.84M-15.01M
Debt / Equity
-0.93x2.12x0.08x0.13x0.30x0.07x0.15x0.05x
Debt / EBITDA
---------0.03x
Net Debt / EBITDA
--------0.68x
Interest Coverage
--21977.91x-567.80x-4260.25x-----
Total Equity
6.81M▲ 0%
4.45M▼ 34.8%
1.96M▼ 56.0%
37.45M▲ 1813.8%
20.5M▼ 45.3%
6.74M▼ 67.1%
21.89M▲ 224.7%
5.67M▼ 74.1%
16.03M▲ 0%
Equity Growth %
--34.77%-55.97%1813.8%-45.26%-67.12%224.68%-74.07%-156.9%
Book Value per Share
4.282.781.1619.809.783.101.470.320.65
Total Shareholders' Equity
6.81M4.45M1.96M37.45M20.5M6.74M21.89M5.67M16.03M
Common Stock
7.11M01.96M21K21K2K14K22K30K
Retained Earnings
000-43.94M-62.77M-84.98M-109.61M-132.31M-137.05M
Treasury Stock
000000000
Accumulated OCI
-1.39M000-357K0000
Minority Interest
000000000

LGVN Cash Flow Statement

Longeveron Inc. (LGVN) cash flow — operating, investing & free cash flow history

MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-5.18M-2.39M-2.36M-9.64M-13.97M-19M-13.87M-18.64M-18.32M
Operating CF Margin %
-242.57%-42.47%-42%-737.83%-1143.13%-2680.11%-579.77%-1555.05%-
Operating CF Growth %
-53.83%1.13%-307.63%-44.97%-36.03%27.02%-34.45%-106.63%
Net Income
-6.34M-2.96M-3.72M-17.05M-18.84M-21.41M-15.97M-22.7M-22.43M
Depreciation & Amortization
745.77K768.84K785.44K914K893K946K958K1.23M1.06M
Stock-Based Compensation
423.87K136.85K83K7.74M2.17M2.03M2.33M1.68M889K
Deferred Taxes
000000000
Other Non-Cash Items
1.9M-120.13K-167-155K1.57M-603K60K97K1.3M
Working Capital Changes
-11.22K-216.48K488.63K-1.09M238K36K-1.24M1.06M861K
Change in Receivables
24.88K-451.46K30.81K366K-164K107K27K-20K-39K
Change in Inventory
00-30.81K-366K00000
Change in Payables
-13.09K0130.94K-945K1.11M0-540K325K-452K
Cash from Investing
-211.68K-125.05K-261.5K-10.7M-677K8.19M-640K-595K-465K
Capital Expenditures
-211.68K-37.57K-261.5K-1.31M-856K-301K-992K-595K-404K
CapEx % of Revenue
9.92%0.67%4.65%100.31%70.05%42.45%41.47%49.62%33.22%
Acquisitions
00085K00000
Investments
---------
Other Investing
-115.72K-87.47K0-9.39M08.49M00-61K
Cash from Financing
1.35M350K1.58M45.17M-509K5.26M28.79M4.67M20.21M
Debt Issued (Net)
00488K-188K00000
Equity Issued (Net)
001.1M45.81M2K-174K12.87M4.98M15.33M
Dividends Paid
000000-8.65M00
Share Repurchases
00000-174K00-194K
Other Financing
1.35M350K-12.67K-451K-511K5.44M24.57M-311K4.88M
Net Change in Cash
-4.04M▲ 0%
-2.17M▲ 46.3%
-1.05M▲ 51.5%
24.84M▲ 2465.7%
-15.15M▼ 161.0%
-5.55M▲ 63.4%
14.28M▲ 357.2%
-14.57M▼ 202.0%
1.43M▲ 0%
Free Cash Flow
-5.39M▲ 0%
-2.43M▲ 54.9%
-2.63M▼ 8.1%
-10.95M▼ 316.9%
-14.82M▼ 35.4%
-19.3M▼ 30.2%
-14.86M▲ 23.0%
-18.89M▼ 27.1%
-18.6M▲ 0%
FCF Margin %
-252.49%-43.14%-46.64%-838.13%-1213.18%-2722.57%-621.24%-1575.48%-1529.61%
FCF Growth %
-54.95%-8.11%-316.93%-35.44%-30.21%23.02%-27.12%-15.21%
FCF per Share
-3.39-1.52-1.56-5.79-7.07-8.88-1.00-1.07-0.75
FCF Conversion (FCF/Net Income)
0.82x0.64x0.64x0.57x0.74x0.89x0.87x0.82x0.83x
Interest Paid
000000000
Taxes Paid
000000000

LGVN Key Ratios

Longeveron Inc. (LGVN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2019202020212022202320242025TTM
Return on Equity (ROE)
-66.09%-116.24%-86.5%-65%-157.19%-111.59%-164.75%-202.41%
Return on Invested Capital (ROIC)
-59.66%-47.23%-129.5%-98.27%-191.89%-312.33%-588.06%-855.68%
Gross Margin
32.44%32.44%45.18%40.67%31.17%78.76%66.97%65.13%
Net Margin
-66.09%-66.1%-1305.13%-1541.33%-3020.17%-667.77%-1893.58%-1844.49%
Debt / Equity
0.93x2.12x0.08x0.13x0.30x0.07x0.15x0.05x
Interest Coverage
-21977.91x-567.80x-4260.25x-----
FCF Conversion
0.64x0.64x0.57x0.74x0.89x0.87x0.82x0.83x
Revenue Growth
163.71%-0.01%-76.8%-6.43%-41.98%237.38%-49.87%-45.35%
Related:LGVN Dividend History·LGVN Revenue History·LGVN Price History·LGVN P/E History·LGVN Financial Ratios·LGVN Institutional Holders

LGVN SEC Filings & Documents

Longeveron Inc. (LGVN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 13, 2026·SEC

Material company update

May 8, 2026·SEC

Material company update

Apr 10, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 17, 2026·SEC

FY 2025

Feb 28, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 13, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 13, 2025·SEC

LGVN Frequently Asked Questions

Longeveron Inc. (LGVN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Longeveron Inc. (LGVN) reported $1.2M in revenue for fiscal year 2025. This represents a 43% decrease from $2.1M in 2018.

Longeveron Inc. (LGVN) saw revenue decline by 49.9% over the past year.

Longeveron Inc. (LGVN) reported a net loss of $22.4M for fiscal year 2025.

Dividend & Returns

Longeveron Inc. (LGVN) has a return on equity (ROE) of -164.7%. Negative ROE indicates the company is unprofitable.

Longeveron Inc. (LGVN) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in LGVN back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

How much would $100/month in LGVN be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →